New drug combo aims to tackle tough blood cancer

NCT ID NCT06327685

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a combination of two drugs, avapritinib and decitabine, for people with a rare blood cancer called systemic mastocytosis with an associated hematologic neoplasm (SM-AHN). The goal is to find a safe dose that can control both parts of the disease. About 34 adults will take part to see how well the combination works and what side effects occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGIC NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGIC NEOPLASM

Contacts and locations

Locations

Dana-Farber Cancer Institute
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States
Mayo Clinic - Arizona
NOT_YET_RECRUITING

Phoenix, Arizona, 85054, United States
Memorial Sloan Kettering Cancer Center
NOT_YET_RECRUITING

New York, New York, 10065, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Stanford University Medical Center
NOT_YET_RECRUITING

Palo Alto, California, 94305, United States
University of Michigan
NOT_YET_RECRUITING

Ann Arbor, Michigan, 48109, United States
University of Utah Health
RECRUITING

Salt Lake City, Utah, 84132, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.